Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes ... care process is the best course of action. We shouldn’t let a patient start with ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Tirzepatide includes blockbuster injected GLP-1 meds Mounjaro (for diabetes ... "FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to ...

Association does not imply causation, and the mechanism of action of these agents ... of patients who filled a prescription for a GLP-1 within at least 90 days before and after surgery and ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 user are significantly reducing their grocery spending. The paper ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

or GLP-1 receptor agonists, were originally solely intended for use as diabetes medications. However, they are now being used for a variety of purposes, including helping people with weight loss. The ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based ... both have a long duration of action, allowing once-daily administration.

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for ...